Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
Open Access
- 28 September 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 390 (10111), 2472-2480
- https://doi.org/10.1016/s0140-6736(17)32149-9
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Bloodstream Infection among Children Presenting to a General Hospital Outpatient Clinic in Urban NepalPLOS ONE, 2012
- Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010Journal of Global Health, 2012
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant VaccinesClinical and Vaccine Immunology, 2011
- Immunity to salmonellosisImmunological Reviews, 2011
- Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young ChildrenThe New England Journal of Medicine, 2003
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenThe New England Journal of Medicine, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiThe New England Journal of Medicine, 1987
- Precise Estimation of the Numbers of Chronic Carriers of Salmonella typhi in Santiago, Chile, an Endemic AreaThe Journal of Infectious Diseases, 1982
- Evaluation of a UDP-Glucose-4-Epimeraseless Mutant of Salmonella typhi as a Live Oral VaccineThe Journal of Infectious Diseases, 1977